VERA · Insider Trading
Vera Therapeutics, Inc. Class A Common Stock
Every open-market purchase and sale reported by VERA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Marshall Fordyce | PRESIDENT AND CEO | MIXED | — | −$630.91K |
| 2026-09-14 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | M | +5,000 | +$19.70K |
| 2026-09-04 | Marshall Fordyce | PRESIDENT AND CEO | MIXED | — | −$596.05K |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | MIXED | — | −$1.82M |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | MIXED | — | −$626.16K |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | MIXED | — | −$648.18K |
| 2026-08-05 | Nancy Lee Boman | Chief Regulatory Officer | A | +44,987 | — |
| 2026-07-09 | Marshall Fordyce | PRESIDENT AND CEO | Sell | −46,250 | −$1.96M |
| 2026-06-24 | Marshall Fordyce | PRESIDENT AND CEO | Sell | −18,500 | −$701.77K |
| 2026-05-26 | Scott W Morrison | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Beth C Seidenberg | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Patrick G Enright | Director | A | +17,084 deriv. | — |
| 2026-05-26 | James R Meyers | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Christy J. Oliger | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Michael Morrissey | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Kimball Hall | Director | A | +17,084 deriv. | — |
| 2026-05-26 | Andrew Cheng | Director | A | +17,084 deriv. | — |
| 2026-05-13 | Marshall Fordyce | PRESIDENT AND CEO | Sell | −18,500 | −$679.75K |
| 2026-04-15 | Marshall Fordyce | PRESIDENT AND CEO | Sell | −22,951 | −$1.01M |
| 2026-03-25 | Jane Wright-Mitchell | Chief Legal Officer | A | +42,403 | — |
| 2026-03-16 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | M | +10,000 | +$39.40K |
| 2026-03-09 | Christopher Hite | Director | A | +24,937 deriv. | — |
| 2026-02-25 | David Lee Johnson | Chief Operating Officer | Sell | −2,579 | −$108.28K |
| 2026-02-25 | William D. Turner | Chief Regulatory Officer | Sell | −2,187 | −$91.82K |
| 2026-02-25 | Robert Brenner | Chief Medical Officer | Sell | −2,151 | −$90.31K |
| 2026-02-25 | Marshall Fordyce | PRESIDENT AND CEO | Sell | −16,925 | −$710.58K |
| 2026-02-25 | Laurence Matthew Skelton | Chief Commercial Officer | Sell | −1,582 | −$66.42K |
| 2026-02-25 | Sean Grant | CHIEF FINANCIAL OFFICER | Sell | −4,949 | −$207.78K |
| 2026-02-25 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | Sell | −3,117 | −$130.86K |
| 2026-02-06 | Sean Grant | CHIEF FINANCIAL OFFICER | A | +25,000 | — |
| 2026-02-06 | David Lee Johnson | Chief Operating Officer | A | +20,000 | — |
| 2026-02-06 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | A | +10,000 | — |
| 2026-02-06 | Laurence Matthew Skelton | Chief Commercial Officer | A | +20,000 | — |
| 2026-02-06 | William D. Turner | Chief Regulatory Officer | A | +25,000 | — |
| 2026-02-06 | Marshall Fordyce | PRESIDENT AND CEO | A | +68,800 | — |
| 2026-02-06 | Robert Brenner | Chief Medical Officer | A | +25,000 | — |
| 2025-12-17 | William D. Turner | Chief Regulatory Officer | MIXED | — | −$345.47K |
| 2025-12-15 | Patrick G Enright | Director | Buy | +5,882 | +$249.99K |
| 2025-12-10 | William D. Turner | Chief Regulatory Officer | MIXED | — | −$297.75K |
| 2025-12-04 | William D. Turner | Chief Regulatory Officer | MIXED | — | −$244.70K |
| 2025-11-26 | James R Meyers | Director | A | +25,000 deriv. | — |
| 2025-11-25 | Jason S Carter | Chief Legal Officer | Sell | −3,864 | −$107.50K |
| 2025-11-13 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | MIXED | −5,000 | −$396.48K |
| 2025-06-25 | Patrick G Enright | Director | Buy | +250,000 | +$5.28M |
| 2025-05-16 | Maha Katabi | Director | A | +14,000 deriv. | — |
| 2025-05-16 | Michael Morrissey | Director | A | +14,000 deriv. | — |
| 2025-05-16 | Christy J. Oliger | Director | A | +14,000 deriv. | — |
| 2025-05-16 | Beth C Seidenberg | Director | A | +14,000 deriv. | — |
| 2025-05-16 | Kimball Hall | Director | A | +14,000 deriv. | — |
| 2025-05-16 | Patrick G Enright | Director | A | +14,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Maha Katabi | Director | 7,062,846 | $217.04M |
| Patrick G Enright | Director | 3,602,475 | $110.70M |
| Marshall Fordyce | PRESIDENT AND CEO | 376,693 | $11.58M |
| Beth C Seidenberg | Director | 135,565 | $4.17M |
| Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 | $3.66M |
| Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 | $2.48M |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 | $1.97M |
| Robert Brenner | Chief Medical Officer | 50,947 | $1.57M |
| Jason S Carter | Chief Legal Officer | 49,136 | $1.51M |
| David Lee Johnson | Chief Operating Officer | 45,727 | $1.41M |
| William D. Turner | Chief Regulatory Officer | 45,313 | $1.39M |
| Nancy Lee Boman | Chief Regulatory Officer | 44,987 | $1.38M |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 | $1.30M |
| Andrew Cheng | Director | 17,488 | $537.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VERA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.